Blood biomarkers to improve diagnosis and management of mild traumatic Brain injury in vulnerable patients.

Font Standard Bold
Login

Research unit

SERI

Project number

23.00484

Project title

Blood biomarkers to improve diagnosis and management of mild traumatic Brain injury in vulnerable patients.

Texts for this project

	German	French	Italian	English
Abstract	-	-	-

Inserted texts

Category	Text
Abstract (English)	Cranial Computed Tomography (CCT), the current standard method to identify intracerebral lesions, is overused in case of mild traumatic brain injury (mTBI). This results in avoidable waiting time in the emergency department (ED), risks of radiation exposure for patients and to a waste of ED resources use and costs. Blood biomarkers of brain injury may correlate with imaging abnormalities and cognitive outcome. In this context, we are conducting a large clinical study (BRAINI) with mTBI adult patients to explore the performance of an automated assay measuring two promising blood biomarkers, GFAP and UCH-L1. BRAINI2 will focus on two poorly explored mTBI populations: the elderly where falls and pre-injury medications with anticoagulant drugs are common, and paediatrics where biomarkers data are very limited. BRAINI2 will establish an age-specific algorithm with objective mTBI diagnostic and prognostic indicators providing economical and health benefits.

Category

Text

Abstract
(English)

Cranial Computed Tomography (CCT), the current standard method to identify intracerebral lesions, is overused in case of mild traumatic brain injury (mTBI). This results in avoidable waiting time in the emergency department (ED), risks of radiation exposure for patients and to a waste of ED resources use and costs. Blood biomarkers of brain injury may correlate with imaging abnormalities and cognitive outcome. In this context, we are conducting a large clinical study (BRAINI) with mTBI adult patients to explore the performance of an automated assay measuring two promising blood biomarkers, GFAP and UCH-L1. BRAINI2 will focus on two poorly explored mTBI populations: the elderly where falls and pre-injury medications with anticoagulant drugs are common, and paediatrics where biomarkers data are very limited. BRAINI2 will establish an age-specific algorithm with objective mTBI diagnostic and prognostic indicators providing economical and health benefits.